Part, Chapter, Paragraph

 1 I, 1,1(8)   |                Arch. Allergy Immunol., 1998, 116: 5-21. ~
 2 I, 1,1(9)   |                Arch. Allergy Immunol., 1998 116: 5-21; Cooper D.K.C.,
 3 I, 1,1(10)  |             transplants. J Clin Invest 1998; 101: 1745-1756. ~
 4 I, 1,1(11)  |              feasible?, J Am Coll Surg 1998, 186 (4): 383-7. ~
 5 I, 1,1(12)  |     transplantation, Annu.Rev.Immunol. 1998, 16: 433-70. ~
 6 I, 2,2(21)  |         rejection, Xenotransplantation 1998, 5: 169-175. ~
 7 I, 2,2(23)  |                prospects, Annu.Rev.Med.1998, 49: 301-10. ~
 8 I, 2,2(25)  |     transplantation, Annu.Rev.Immunol. 1998, 16: 433-70. ~
 9 I, 2,4(39)  | xenotransplantation, Ann. NY Acad. Sc. 1998, 862: 121-124. ~
10 I, 2,5(44)  |           therapy, Curr Opin Chem Biol 1998, 2: 512-8. ~
11 II, 1,11(61)|                e attualità, Med. Mor., 1998, 48, 15-46. ~
12 II, 2,12(64)|      Collective Risk, Nature Medicine, 1998, 4:  141-144; Hughes J.,
13 II, 2,12(64)|             Journal of Medical Ethics, 1998, 24: 18-24; Vanderpool H.
14 II, 2,12(64)|           Xenotransplants, The Lancet, 1998, 351: 1347-1350; Clark M.A.,
15 II, 2,17(71)|       economics, Food Drug Law Journal 1998, 53 (2): 353-384; Urruela
16 II, 2,18(73)|              Law International, London 1998:  145-150; Accordo di Marrakech